Cited by 246SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19

Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections

Open access
Taquet, Maxime, Dercon, Quentin, Harrison, Paul J.·2022·Brain, Behavior, and Immunity

Published version of a preprint

Abstract

Vaccination has proven effective against infection with SARS-CoV-2, as well as death and hospitalisation following COVID-19 illness. However, little is known about the effect of vaccination on other acute and post-acute outcomes of COVID-19. Data were obtained from the TriNetX electronic health records network (over 81 million patients mostly in the USA). Using a retrospective cohort study and time-to-event analysis, we compared the incidences of COVID-19 outcomes between individuals who received a COVID-19 vaccine (approved for use in the USA) at least 2 weeks before SARS-CoV-2 infection and propensity score-matched individuals unvaccinated for COVID-19 but who had received an influenza vaccine. Outcomes were ICD-10 codes representing documented COVID-19 sequelae in the 6 months after a confirmed SARS-CoV-2 infection (recorded between January 1 and August 31, 2021, i.e. before the emergence of the Omicron variant). Associations with the number of vaccine doses (1 vs. 2) and age (<60 vs. ≥ 60 years-old) were assessed. Among 10,024 vaccinated individuals with SARS-CoV-2 infection, 9479 were matched to unvaccinated controls. Receiving at least one COVID-19 vaccine dose was associated with a significantly lower risk of respiratory failure, ICU admission, intubation/ventilation, hypoxaemia, oxygen requirement, hypercoagulopathy/venous thromboembolism, seizures, psychotic disorder, and hair loss (each as composite endpoints with death to account for competing risks; HR 0.70-0.83, Bonferroni-corrected p < 0.05), but not other outcomes, including long-COVID features, renal disease, mood, anxiety, and sleep disorders. Receiving 2 vaccine doses was associated with lower risks for most outcomes. Associations between prior vaccination and outcomes of SARS-CoV-2 infection were marked in those <60 years-old, whereas no robust associations were observed in those ≥60 years-old. In summary, COVID-19 vaccination is associated with lower risk of several, but not all, COVID-19 sequelae in those with breakthrough SARS-CoV-2 infection. The findings may inform service planning, contribute to forecasting public health impacts of vaccination programmes, and highlight the need to identify additional interventions for COVID-19 sequelae.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbi.2022.04.013

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

5 of the 37 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Taquet, M., Dercon, Q., & Harrison, P. J.
Affiliations
  • Oxford Health NHS Foundation Trust (GB)
  • MRC Cognition and Brain Sciences Unit (GB)
Corresponding author
Taquet, Maxime
Venue
Brain, Behavior, and Immunity
Publisher
Elsevier BV
Published
2022-07
Volume
103
Pages
154-162
ISSN
0889-1591 (ISSN-L)
OpenAlex
W4225562523
Cited by
246
References
37
Citations by year
2026: 8 · 2025: 28 · 2024: 68 · 2023: 79 · 2022: 60 · 2021: 2 · 2013: 1
FWCI
28.72
Type
journal article
Language
en
Open access
Locations
  • Brain Behavior and Immunity (publishedVersion, cc-by)
  • medRxiv (acceptedVersion, cc-by-nc)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Apollo (University of Cambridge) (submittedVersion)
  • Apollo
Funders
  • National Institute for Health and Care Research
  • AXA Research Fund (G102329)
  • NIHR Oxford Biomedical Research Centre (BRC-1215-20005)
  • Medical Research Council (SUAG/077 G101400)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Neurology › Long-Term Effects of COVID-19
Keywords
breakthrough infection, SARS-CoV-2, post-COVID-19 sequelae, long COVID, respiratory failure, intensive care unit admission, intubation and mechanical ventilation, hypoxemia, venous thromboembolism, hypercoagulability, seizures, psychosis, hair loss, vaccine dose number, older adults, Omicron variant
MeSH terms
COVID-19, SARS-CoV-2, COVID-19 Vaccines, Post-Acute COVID-19 Syndrome, Humans, Middle Aged, Retrospective Studies, Vaccination, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review